The essentials to start with
How is it supposed to work?
Retatrutide activates three receptor types: GIP, GLP-1 and glucagon. A receptor is a site through which a cell receives a particular signal. These systems help regulate appetite and nutrient metabolism. Combining their actions in one substance is one reason for researchers' interest. [3] [6]
We explain more in the short article “How do peptides work in the body?”.
Does it help with weight loss?
One study enrolled more than 2,300 adults with obesity without diabetes. After about a year and a half, the group receiving the highest studied dose had lost an average of 25% of body weight. [7]
At a weight of 100 kg, that would mean 25 kg less. This is an example of converting percentages to kilograms. It does not mean that everyone will lose that amount.
Participants were cared for by the study team. An average result does not tell us how a particular person will respond. The comparison also matters: the difference between groups helps separate the substance's effect from other changes during the study.
I want to see the exact study data
The trial was called TRIUMPH-1 and involved 2,339 people. After 80 weeks, the result for retatrutide 12 mg was −25.0%. The dose identifies the study group; it is not a recommendation for use. [7]
A placebo is a preparation without the substance being studied. The analysis also accounted for treatment discontinuation. Its technical name is the treatment-regimen estimand.
What side effects are possible?
In the trial involving people with type 2 diabetes, nausea and diarrhoea were common. Low blood pressure and unusual skin sensations were also reported. Some people had to stop treatment. [8]
We do not yet know every possible effect after many years. Weight loss alone also does not prove that retatrutide extends life. That requires separate studies.
Assessing treatment involves more than kilograms lost. How many people could continue treatment and how serious the problems were matter just as much. A favourable group average does not determine safety for an individual patient.
Can it already be bought at a pharmacy?
Retatrutide is not yet an approved medicine available through ordinary sale. An online offer does not mean that a product has been checked. Medicines regulators warn about this. [10] [6]
Taking part in a clinical trial and buying a preparation independently are different situations. A trial has defined eligibility, supervision and health-problem reporting procedures. A label on a purchased vial does not provide that oversight. [5]
It is also uncertain whether a vial bought online contains what the seller claims. See an example of a product with contents different from its label.
Frequently asked questions
Is retatrutide better than other weight-loss medicines?
There is no single answer for everyone. Both weight loss and side effects need to be compared. The trial directly comparing retatrutide with tirzepatide is still ongoing. [12]
Could retatrutide help people live longer?
We do not know. Losing weight does not in itself prove that someone will live longer. The study of retatrutide's effects on the heart and kidneys is still ongoing. [13]
When will retatrutide be available, and how much will it cost?
We do not give a firm date or price. Study results and authorisation for use as a medicine are needed first. [6]
What is new about retatrutide?
Retatrutide and weight loss. What do new studies show? — we explain the latest findings and what they still cannot tell us.
Where does this information come from?
Show sources and how they were checked
- NCI: Receptor
Scientific glossary · full definition reviewed. Accessed: 2 November 2026.
- Lilly: What to know about retatrutide
Manufacturer information · October 2026 · full page. Accessed: 2 November 2026.
- Jastreboff i wsp.: TRIUMPH-1, NEJM
Phase 3 trial publication · online 29 September 2026 · PubMed abstract reviewed · DOI: 10.1056/NEJMoa2604169. Accessed: 2 November 2026.
- Bellido i wsp.: TRIUMPH-2, The Lancet
Phase III study publication · online 29.09.2026, issue 10.10.2026 · PubMed abstract read · DOI: 10.1016/S0140-6736(26)01861-1. Accessed: 02.11.2026.
- FDA: Concerns with Unapproved GLP-1 Drugs
US regulator announcement · full page. Accessed: 02.11.2026.
- ClinicalTrials.gov: TRIUMPH-5 (NCT06662383)
Trial registry · API accessed 2 November 2026 · record updated 20 July 2026. Accessed: 2 November 2026.
- ClinicalTrials.gov: TRIUMPH-Outcomes (NCT06383390)
Trial registry · API accessed 2 November 2026 · record updated 8 October 2026. Accessed: 2 November 2026.
- NIH / NEI: Learn About Clinical Trials
Public institution guide · full page. Accessed: 2 November 2026.